Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Robin Carhart‐Harris, Mark Bolstridge, Camilla Day, et al.
Psychopharmacology (2017) Vol. 235, Iss. 2, pp. 399-408
Open Access | Times Cited: 774

Showing 1-25 of 774 citing articles:

Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1402-1411
Open Access | Times Cited: 1007
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Robin Carhart‐Harris, Karl Friston
Pharmacological Reviews (2019) Vol. 71, Iss. 3, pp. 316-344
Open Access | Times Cited: 784
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman, David Nutt, Robin Carhart‐Harris
Frontiers in Pharmacology (2018) Vol. 8
Open Access | Times Cited: 646
Serotonin and brain function: a tale of two receptors
RL Carhart-Harris, DJ Nutt
Journal of Psychopharmacology (2017) Vol. 31, Iss. 9, pp. 1091-1120
Open Access | Times Cited: 597
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin Carhart‐Harris, Guy M. Goodwin
Neuropsychopharmacology (2017) Vol. 42, Iss. 11, pp. 2105-2113
Open Access | Times Cited: 505
The entropic brain - revisited
Robin Carhart‐Harris
Neuropharmacology (2018) Vol. 142, pp. 167-178
Closed Access | Times Cited: 434
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, et al.
Pharmacology & Therapeutics (2018) Vol. 197, pp. 83-102
Closed Access | Times Cited: 421
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Franz X. Vollenweider, Katrin H. Preller
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 611-624
Closed Access | Times Cited: 415
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
Kuglae Kim, Tao Che, Ouliana Panova, et al.
Cell (2020) Vol. 182, Iss. 6, pp. 1574-1588.e19
Open Access | Times Cited: 375
Novel and emerging treatments for major depression
Steven Marwaha, Edward Palmer, Trisha Suppes, et al.
The Lancet (2022) Vol. 401, Iss. 10371, pp. 141-153
Open Access | Times Cited: 315
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 300
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1076-1087
Closed Access | Times Cited: 294
Psychiatry & the psychedelic drugs. Past, present & future
James Rucker, Jonathan Iliff, David Nutt
Neuropharmacology (2017) Vol. 142, pp. 200-218
Open Access | Times Cited: 279
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 17
Open Access | Times Cited: 266
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 259
Psychedelic Psychiatry’s Brave New World
David Nutt, David Erritzøe, Robin Carhart‐Harris
Cell (2020) Vol. 181, Iss. 1, pp. 24-28
Open Access | Times Cited: 257
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Charles L. Raison, Gerard Sanacora, Joshua D. Woolley, et al.
JAMA (2023) Vol. 330, Iss. 9, pp. 843-843
Open Access | Times Cited: 234
Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial
Robin von Rotz, Eva Maria Schindowski, Johannes Jungwirth, et al.
EClinicalMedicine (2022) Vol. 56, pp. 101809-101809
Open Access | Times Cited: 226
Effects of psilocybin therapy on personality structure
David Erritzøe, Leor Roseman, Matthew M. Nour, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 138, Iss. 5, pp. 368-378
Open Access | Times Cited: 225
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Silvia Muttoni, Maddalena Ardissino, Christopher John
Journal of Affective Disorders (2019) Vol. 258, pp. 11-24
Closed Access | Times Cited: 221
Structure-based discovery of nonhallucinogenic psychedelic analogs
Dongmei Cao, Jing Yu, Huan Wang, et al.
Science (2022) Vol. 375, Iss. 6579, pp. 403-411
Closed Access | Times Cited: 215
Designer drugs: mechanism of action and adverse effects
Dino Luethi, Matthias E. Liechti
Archives of Toxicology (2020) Vol. 94, Iss. 4, pp. 1085-1133
Open Access | Times Cited: 213
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
B. Anderson, Alicia Danforth, Prof Robert Daroff, et al.
EClinicalMedicine (2020) Vol. 27, pp. 100538-100538
Open Access | Times Cited: 204
Psychedelics as anti-inflammatory agents
Thomas W. Flanagan, Charles D. Nichols
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 363-375
Closed Access | Times Cited: 199
DMT Models the Near-Death Experience
Christopher Timmermann, Leor Roseman, L. Williams, et al.
Frontiers in Psychology (2018) Vol. 9
Open Access | Times Cited: 191
Page 1 - Next Page

Scroll to top